Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Medtronic
Accenture
US Army
Daiichi Sankyo
Harvard Business School
Mallinckrodt
US Department of Justice
Moodys

Generated: February 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,815,801

« Back to Dashboard

Summary for Patent: 8,815,801
Title:Controlled release composition and method of producing the same
Abstract: A controlled release composition containing a physiologically active substance in high content, suppressing the initial excess release, and achieving a stable release speed over a long period of time is provided. A controlled release composition comprising (1) a physiologically active substance or salt thereof in an amount of about 14% (w/w) to about 24% (w/w) based on the total composition weight, (2) hydroxynaphthoic acid selected from the group consisting of 3-hydroxy-2-naphthoic acid and 1-hydroxy-2-naphthoic acid or salt thereof, and (3) a lactic acid polymer or salt thereof having a weight-average molecular weight of 15000 to 50000 in which the content of polymers having molecular weights of 5000 or less is about 5% by weight or less, wherein the molar ratio of said hydroxynaphthoic acid or salt thereof to said physiologically active substance or salt thereof is from 3:4 to 4:3.
Inventor(s): Yamamoto; Kazumichi (Kyoto, JP), Yamada; Akiko (Kyoto, JP), Hata; Yoshio (Hokkaido, JP)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:13/548,463
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 8,815,801

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Abbvie Endocrine Inc LUPRON DEPOT leuprolide acetate INJECTABLE;INJECTION 020517-003 Jun 17, 2011 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,815,801

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2001-199484Jun 29, 2001
Japan2001-340993Nov 6, 2001

Non-Orange Book US Patents Family Members for Patent 8,815,801

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,429,559 Controlled release composition and method of producing the same ➤ Try a Free Trial
8,067,030 Controlled release composition and method of producing the same ➤ Try a Free Trial
8,246,987 Controlled release composition and method of producing the same ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,815,801

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 034641 ➤ Try a Free Trial
Argentina 098261 ➤ Try a Free Trial
Austria 326264 ➤ Try a Free Trial
Austria 387937 ➤ Try a Free Trial
Austria 509668 ➤ Try a Free Trial
Australia 2002311631 ➤ Try a Free Trial
Australia 2006246508 ➤ Try a Free Trial
Brazil 0210561 ➤ Try a Free Trial
Canada 2455392 ➤ Try a Free Trial
China 100348265 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Cipla
Cantor Fitzgerald
QuintilesIMS
Merck
Harvard Business School
Covington
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot